

**SUMMARY:** The Health Resources and Services Administration (HRSA) will be issuing non-competitive supplemental funding to the Maternal Child and Health Bureau's (MCHB) Comprehensive Hemophilia Diagnostic and Treatment Centers. MCHB's Division of Children with Special Health Needs and the Genetic Services Branch are currently undergoing a strategic planning process. This will provide feasible time for the MCHB to

align fiscal resources and programmatic goals as determined by this strategic planning process with the least disruption to the States, communities, and constituencies that currently receive assistance and services from these grantees.

**SUPPLEMENTARY INFORMATION:** *Intended Recipient of the Award:* Comprehensive Hemophilia Diagnostic and Treatment Centers—12 Regional Centers (see table below).

*Amount of the Award:* 12 awards ranging from \$184,846 to \$595,453.

*CFDA Number:* 93.110.

*Project Period:* The period of supplemental support is from June 1, 2011, to May 31, 2012.

**Authority:** This activity is under the authority of Section 501(a) (2) of the Social Security Act, the Maternal and Child Health Federal Set-Aside Program: Special Projects of Regional and National Significance (SPRANS) (42 U.S.C. 701).

#### REGIONAL COMPREHENSIVE HEMOPHILIA DIAGNOSTIC AND TREATMENT CENTERS

Grantee	Grant No.	Region	FY 2010 Funding Level
University of Massachusetts .....	H30 MC00037–12–00.	Region 1 .....	\$312,472
Mt. Sinai School of Medicine .....	H30 MC00019–20–00.	Region 2 .....	595,453
Children's Hospital of Philadelphia .....	H30 MC09625–02–00.	Region 3 .....	530,808
University of North Carolina .....	H30 MC05053–07–01.	Region 4–N .....	329,980
Hemophilia of Georgia .....	H30 MC00011–20–00.	Region 4–S .....	228,857
Hemophilia Foundation of Michigan .....	H30 MC00015–20–00.	Region 5–E .....	365,256
Great Lakes Hemophilia Foundation .....	H30 MC00032–21–02.	Region 5–W .....	446,520
University of Texas HSC at Houston .....	H30MC00029–20–06.	Region 6 .....	455,871
Children's Mercy Hospital .....	H30 MC00040–10–00.	Region 7 .....	371,228
University of Colorado .....	H30 MC00008–20–00.	Region 8 .....	321,921
Children's Hospital of Orange County .....	H30 MC00036–12–00.	Region 9 .....	714,832
Oregon Health and Science University .....	H30 MC00025–20–00.	Region 10 .....	184,846

#### Justification for the Exception to Competition

Since the inception of HRSA's genetic services program, the landscape of our health care system has changed dramatically. In addition, our knowledge base for genetic medicine in general and blood disorders in particular has expanded. Unfortunately, the changes in our knowledge base and standards of care are not currently reflected in what we measure through this program nor how they are integrated into day to day activities that influence the health of individuals with hemophilia, thrombophilia and von Willebrand Disease and other congenital bleeding disorders.

To better reflect the current landscape, the MCHB is undertaking a strategic planning process this year. At the end of the process, we hope to have better defined measures that will reflect our new plan and the goals for the next 10 years. This will provide us with the basis to expand the applicant pool as

well as improve the evidence base for the utility of the National Hemophilia Program.

MCHB proposes this course of action for three reasons: (1) To appropriately respond to the directions that will be outlined after the strategic planning process, (2) to provide for sufficient fiscal resource to continue programmatic activities at current levels, and (3) to maintain MCH programmatic support with the least disruption to the State, community, and MCH constituencies who are currently receiving assistance and services from these grantees and the grantees themselves. Without this approach, the programmatic changes indicated through the strategic planning process will not be outlined nor implemented for another 3 years when the next competitive process will begin. Delaying the competition into mid fiscal year 2011 ensures continuity of funding for all eligible entities, with no eligible entity being harmed by the extension.

**FOR FURTHER INFORMATION CONTACT:** Sara Copeland, M.D., Maternal and Child Health Bureau, Health Resources and Services Administration, Room 18A–19, Parklawn Building, 5600 Fishers Lane, Rockville, Maryland 20857, Telephone (301) 443–8860, [scopeland@hrsa.gov](mailto:scopeland@hrsa.gov).

Dated: April 12, 2011.

**Mary K. Wakefield,**

Administrator.

[FR Doc. 2011–9269 Filed 4–15–11; 8:45 am]

**BILLING CODE 4165–15–P**

#### DEPARTMENT OF HEALTH AND HUMAN SERVICES

##### National Institutes of Health

##### National Institute of Allergy and Infectious Diseases; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as

amended (5 U.S.C. App.), notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Institute of Allergy and Infectious Diseases Special Emphasis Panel; Preclinical Services for the Development of Biopharmaceutical Products for Infectious Diseases.

*Date:* May 11, 2011.

*Time:* 12 p.m. to 6 p.m.

*Agenda:* To review and evaluate contract proposals.

*Place:* National Institutes of Health, 6610 Rockledge Drive, Bethesda, MD 20892.

*Contact Person:* Yong Gao, PhD, Scientific Review Officer, Scientific Review Program, DHHS/NIH/NIAID, 6700B Rockledge Drive, Room 3246, Bethesda, MD 20892, 301-443-8115, [gaol2@niaid.nih.gov](mailto:gaol2@niaid.nih.gov).

*Name of Committee:* National Institute of Allergy and Infectious Diseases Special Emphasis Panel; Immune Response to Viral Infections.

*Date:* May 12, 2011.

*Time:* 11 a.m. to 4 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, 6700B Rockledge Drive, Bethesda, MD 20817. (Telephone Conference Call.)

*Contact Person:* Richard W. Morris, PhD, Scientific Review Officer, Scientific Review Program, DEA/NIAID/NIH/DHHS, Room 2217, 6700-B Rockledge Drive, MSC-7616, Bethesda, MD 20892-7616, 301-496-2550, [rmorris@niaid.nih.gov](mailto:rmorris@niaid.nih.gov).

(Catalogue of Federal Domestic Assistance Program Nos. 93.855, Allergy, Immunology, and Transplantation Research; 93.856, Microbiology and Infectious Diseases Research, National Institutes of Health, HHS)

Dated: April 12, 2011.

**Jennifer S. Spaeth,**

*Director, Office of Federal Advisory Committee Policy.*

[FR Doc. 2011-9322 Filed 4-15-11; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### Office of the Director, National Institutes of Health; Notice of Meeting

Pursuant to section 10(a) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is

hereby given of a meeting of the Director's Council of Public Representatives.

The meeting will be open to the public, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting.

*Name of Committee:* Director's Council of Public Representatives.

*Date:* May 6, 2011.

*Time:* 1:30 p.m. to 3:30 p.m.

*Agenda:* The Council will discuss issues related to how best to gather input from the public as well as how COPR can assist in promoting K-12 education. Further information will be available on the COPR Web site.

*Place:* National Institutes of Health, Building 31, Conference Room 6, 31 Center Drive, Bethesda, MD 20892.

*Contact Person:* Sheria Washington, Executive Secretary/Outreach Program Specialist, Office of Communications and Public Liaison, Office of the Director, National Institutes of Health, 1 Center Drive, Room 331, Bethesda, MD 20892, 301-594-4837, [Sheria.Washington@nih.gov](mailto:Sheria.Washington@nih.gov).

Any interested person may file written comments with the committee by forwarding the statement to the Contact Person listed on this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person.

In the interest of security, NIH has instituted stringent procedures for entrance onto the NIH campus. All visitor vehicles, including taxicabs, hotel, and airport shuttles will be inspected before being allowed on campus. Visitors will be asked to show one form of identification (for example, a government-issued photo ID, driver's license, or passport) and to state the purpose of their visit.

Information is also available on the Institute's/Center's home page: <http://www.copr.nih.gov>, where an agenda and any additional information for the meeting will be posted when available.

(Catalogue of Federal Domestic Assistance Program Nos. 93.14, Intramural Research Training Award; 93.22, Clinical Research Loan Repayment Program for Individuals from Disadvantaged Backgrounds; 93.232, Loan Repayment Program for Research Generally; 93.39, Academic Research Enhancement Award; 93.936, NIH Acquired Immunodeficiency Syndrome Research Loan Repayment Program; 93.187, Undergraduate Scholarship Program for Individuals from Disadvantaged Backgrounds, National Institutes of Health, HHS.)

Dated: April 12, 2011.

**Jennifer S. Spaeth,**

*Director, Office of Federal Advisory Committee Policy.*

[FR Doc. 2011-9320 Filed 4-15-11; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HOMELAND SECURITY

[DHS Docket No. DHS-2009-0032]

### Guidance to Federal Financial Assistance Recipients Regarding Title VI Prohibition Against National Origin Discrimination Affecting Limited English Proficient Persons

**AGENCY:** Office for Civil Rights and Civil Liberties, DHS.

**ACTION:** Notice; final policy guidance.

**SUMMARY:** The Department of Homeland Security is finalizing guidance to recipients of Federal financial assistance regarding Title VI's prohibition against national origin discrimination affecting persons with limited English proficient persons. This guidance is issued pursuant to Executive Order 13166 and is consistent with government-wide guidance previously issued by the Department of Justice.

**DATES:** This guidance is effective May 18, 2011.

**FOR FURTHER INFORMATION CONTACT:** Rebekah Tosado, Senior Advisor to the Officer for Civil Rights and Civil Liberties, Office for Civil Rights and Civil Liberties, Department of Homeland Security, 245 Murray Lane, SW., Building 410, Washington, DC 20528, Mail Stop 0190. Toll free: 1-866-644-8360 or TTY 1-866-644-8361. Local: 202-401-1474 or TTY: 202-401-0470.

**SUPPLEMENTARY INFORMATION:** Executive Order 13166 directs each Federal agency that extends assistance subject to the requirements of Title VI of the Civil Rights Act of 1964, 42 U.S.C. 2000d, *et seq.*, to publish guidance for its respective recipients clarifying that obligation. Executive Order 13166, *Improving Access to Services for Persons with Limited English Proficiency*, 65 FR 50121 (August 11, 2000). Executive Order 13166 further directs that all such guidance documents be consistent with the compliance standards and framework detailed by the Department of Justice (DOJ). See *Enforcement of Title VI of the Civil Rights Act of 1964—National Origin Discrimination Against Persons with Limited English Proficiency*, 65 FR 50123 (August 16, 2000) (DOJ Agency LEP Guidance).

The Department of Homeland Security (DHS) adopts guidance that adheres to the Government-wide compliance standards and framework detailed in the DOJ Agency LEP Guidance and in the DOJ's own guidance to its financial assistance recipients. *Guidance to Federal Financial Assistance Recipients*